Search Scholars Central
Articles, journals and conferences in one search. An exact title, DOI or ISSN is listed first.
Advanced searchHide advanced search
In the search box: "exact phrase" · -leave out · OR · prefix* · title: author: journal:
Conference abstract · 28 Mar 2019 Conference abstract · 26 Oct 2015 Development of bio-similar to exendin-4, a major drug for type 2 diabetes
similar), comparable and equivalent to the branded therapeutic product. As, there is no single bio-similar developed or approved for ByettaÃ?®, we have developed the bio-similar of it using
Conference abstract · 3 Aug 2015 How to market generics and bio-similars in Saudi Arabia
branded drugs. In general, the Saudi FDA (SFDA) regulations governing are very similar to FDA regulations, which guarantee the need for worldwide harmonization. Exceptions adopted to meet the specific needs…
Conference abstract · 3 Aug 2015 The flexibilities for the regulatory guidelines for the bio-similars in emerging markets
keystones in establishing a well-set ruling system to be adhered to when developing bio-similars either during or after the expiry of the patents of the innovator drugs ... emerging markets like India. The operational…
Conference abstract · 26 Apr 2018 Innovative, cost effective solution for self-administration of bio-similar drugs
advantages of safe and simplicity but pose an additional cost of materials to a bio-similar drug/molecule. Reusable auto injectors are more cost effective, but the ones
Conference abstract · 18 Mar 2019 Realistic considerations for bio-similar nutraceuticals: challenges and solutions?
Bio-similar nutraceuticals: Th e nutraceuticals market is growing signifi cantly, and a day is not far it will surpass the pharmaceutical market. Th e forecast for nutraceuticals market
Conference abstract · 23 Nov 2012 An update on regulatory approval pathway of bio-similar products
Bio-similar or follow-on biologics are terms used to describe officially-approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry
Conference abstract · 26 Oct 2015 Bio-similar development and production
product in addition to other challenges in product development from laboratory to manufacturing scale. Bio-similar from process development, pre-clinical trials and clinical trials up to fill finish meets
Conference abstract · 15 May 2017 Innovative, cost effective solution for self-administration of bio-similar drugs
advantages of safe and simplicity, but pose an additional cost of materials to a bio-similar drug/molecule. Reusable auto injectors are more cost effective, but the ones
Conference abstract · 3 Jan 2018 Bio-similar in inflammatory bowel disease: A review of post-marketing experience
first to lose the patent, whereas CT-P13 (Celltrion) has been the first infliximab bio-similar to be available. The clinical trial program of CT-P13 has been performed
Conference abstract · 10 Jul 2018 Retrospective efficacy and safety analysis of Zybev (bio-similar of Bevacizumab) use at tertiary eye care centers in India: Spectra study
This retrospective analysis provides real time evidence regarding the efficacy and safety profile of bio-similar of Bevacizumab, Zybev. However, more long term, prospective safety and efficacy studies are still
Conference abstract · 27 Oct 2014 Bio-similars, neoterics of pharmaceuticals
designer molecules derived from living organisms. WHO defines Biosimilars as ?A bio therapeutic product which is similar in terms of quality, safety and efficacy to an already licensed reference bio
Conference abstract · 26 Oct 2015 Comparison between bio-similar filgrastim vs. other G-CSF formulations (originator filgrastim, peg-filgrastim and lenograstim) after autologous stem cell transplantation: A retrospective survey from the Rome Transplant N
Only limited data have been so far published about the use of
Editorial · 29 Aug 2023 Exchanging among rheumatologists' view of non-clinical custom and Bio-similar biologics
Foundation The finish of this study was to assess rheumatologists' appreciations of
Opinion · 8 Sep 2022 Estimation of Bio Similarity between Biological Products
Opinion · 22 Apr 2022 High Decision Mass Spectrometry Pembrolizumab Bio similar
Conference abstract · 20 Aug 2018 Decoding how key stakeholders drive bio similar adoption
When preparing to launch a biosimilar, key distinctions from traditional biologic product
Conference abstract · 15 May 2017 Physicochemical and functional characterization of a bio-similar Bevacizumab
Bevacizumab is a recombinant human IgG1 monoclonal antibody (mAb) glycoprotein consisting of
Market analysis · 30 Apr 2021 International conference on Dental Education
We would like to invite all the participants to the 25th International
Mini review · 17 Jan 2022 Biopharmaceutical development and process using in current research.
significant part in the advancement of biopharmaceuticals. One huger gathering of biopharmaceuticals are bio similar. Their presentation in the European Union and, as of late, the Unites States markets will ... field of…
Conference abstract · 26 Oct 2015 Biosimilars in Europe – the role of EMA's guidelines
In Europe biosimilars are governed by the statutory provisions applicable for generic
Conference abstract · 7 Jul 2021 Sudden and unique mass social bio-mathematical self-similarity between nano and human scales: molecular and textual viruses as collaborating and competing T-strings
Statement of the Problem: Even after the invention of the light microscope
Review article · 1 Oct 2019 Biosimilar Drug Development and Approval Process
highly similar to a licensed reference product. It is recommended that a proposed bio similar product be tested for intended clinical use described in the licensed reference product’s labeling ... protocol requires a…
Conference abstract · 18 Jul 2019 Navigating the biosimilar journey from bench to market: A general overview and case studies
Bio similarity is the regulatory term used to denote the comparability between a biosimilar and its reference medicinal product. Regulatory bodies across the world recommend a stepwise approach to demonstrate ... bio…

